Replicate design(s): why not? [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2011-04-05 12:05 (5565 d 04:28 ago) – Posting: # 6859
Views: 3,784

Hey LB,

❝ There was one more observation in one of the study for Canada Market

❝ Out of 72 volunteer 2 showed 0 absorption for reference!!!

❝ Looks like buggers :angry: threw the formulations away!!


❝ Though the study is passing with and without those volunteers and we have decided to submit the same to the Health Canada.


❝ But I would like to ask that in such condition, how one should handle it?

❝ Any suggestion??:confused:


If I understand you correctly, in two cases you have a series of BLQ and that would be highly unexpected. Given what you know about the assay, the formulations, the metabolism, the genetics, is it plausible to see 2 flat lines in the study if the subjects were properly dosed, sampled and analysed? It shouldn't be.
This is a case where you could do a for-cause audit. Look with your own eyes and ask the difficult questions to see if you can identify a root cause, and to evaluate if you would use the same CRO again.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
320 visitors (0 registered, 320 guests [including 22 identified bots]).
Forum time: 16:34 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5